23AndMe Completes $27.8 Million Series B Round
The last few months have been rocky for the company. In September, co-founder Linda Avey left 23andMe to start a foundation dedicated to studying Alzheimer’s disease. In late October, the company laid off a substantial chunk of its workforce, but declined to comment on how many people were affected.
23andMe is one of the first personal genomics companies, allowing customers to have portions of their DNA analyzed for around $400 (there are a few different products available). After completing a test, customers can log into the site to get reports on their genetic makeup, including a listing of some diseases they may be at risk for.